Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. The commercial-stage biopharmaceutical company, which develops cell and gene therapies for serious diseases, made the announcement on October 20, 2025.
"We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."
Extensive Clinical Development Experience
Dr. Gow brings over 20 years of industry experience in clinical development and medical affairs and is recognized as an expert in gene therapy, especially in ophthalmology. His clinical development track record includes leading programs from Phase 1 through post-marketing studies, which led to the FDA approvals of Xibrom, Bromday, Prolensa, Bepreve and global regulatory approvals of Xiidra.
Prior to joining Abeona, Dr. Gow held executive leadership roles at several pharmaceutical and biotechnology companies, including Shire, Takeda, Novartis, Biogen and SparingVision. His educational background includes an MD from the University of Manitoba, an MBA from Cornell University, a Master of Science in Healthcare Policy and Research from Cornell University, and a Master in Health Care Management from Harvard University.
Abeona's Commercial and Development Portfolio
Abeona Therapeutics is a commercial-stage biopharmaceutical company with ZEVASKYN® (prademagene zamikeracel) as its flagship product. ZEVASKYN is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company operates a fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, which serves as the manufacturing site for ZEVASKYN commercial production.
The company's development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases, positioning the company at the forefront of gene therapy innovation.
